
Sign up to save your podcasts
Or


This week, the FDA fully approved a new drug meant to combat the effects of Alzheimer's disease. Whom will this ultimately benefit? Jearlyn asks Sue Parriott, CEO of the Minnesota-North Dakota chapter of the Alzheimer's Association.
By Audacy5
33 ratings
This week, the FDA fully approved a new drug meant to combat the effects of Alzheimer's disease. Whom will this ultimately benefit? Jearlyn asks Sue Parriott, CEO of the Minnesota-North Dakota chapter of the Alzheimer's Association.

1,725 Listeners

709 Listeners

1,371 Listeners

1,172 Listeners

1,024 Listeners

754 Listeners

333 Listeners

728 Listeners

2,387 Listeners

1,281 Listeners